DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

Phase 2

Terminated

Conditions: Refractory Aplastic Anemia

Interventions: Drug: Decitabine

First Posted Date: 2021-04-22

Last Posted Date: 2022-08-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 3

Registration Number: NCT04854889

Locations: 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

Gene Therapy for Chinese Hemophilia A

Not Applicable

Recruiting

Conditions: Gene Therapy
Hemophilia A

Interventions: Genetic: Injection of GS001

First Posted Date: 2021-01-28

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 12

Registration Number: NCT04728841

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients

Conditions: Pulmonary Fungal Infection

First Posted Date: 2021-01-27

Last Posted Date: 2021-01-27

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 360

Registration Number: NCT04725942

Locations: 🇨🇳
The Second Hospital of Hebei Medical University, Shijia Zhuang, China
🇨🇳
Shanxi Bethune Hospital, Taiyuan, China
🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China

and more 1 locations

Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

Early Phase 1

Conditions: Non-Hodgkin's Lymphoma (NHL)
Peripheral T Cell Lymphoma (PTCL)

Interventions: Biological: Ex-vivo expanded allogeneic γδT cells

First Posted Date: 2021-01-06

Last Posted Date: 2021-01-06

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 10

Registration Number: NCT04696705

Locations: 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China

Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

Phase 2

Recruiting

Conditions: Allergic Transfusion Reaction

Interventions: Drug: Placebo
Drug: Chlorpheniramine

First Posted Date: 2020-12-30

Last Posted Date: 2023-11-28

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 6642

Registration Number: NCT04688736

Locations: 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
The Second Affilated Hospital of Shandong First Medical University, Tai'an, Shandong, China

and more 1 locations

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Phase 1

Completed

Conditions: Large B-cell Lymphoma

Interventions: Biological: CNCT19
Drug: Gemcitabine Injection
Drug: busulfan
Drug: Melphalan Injection

First Posted Date: 2020-12-30

Last Posted Date: 2025-05-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT04690192

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

National Longitudinal Cohort of Hematological Diseases

Recruiting

Conditions: Myeloid Leukemias, Acute
MDS
Lymphoma
Blood Disease Infection
Leukemias, Acute Myeloid
Hemophilia As
Hemophilia Bs
Bone Marrow Transplantation
Myeloma, Multiple
Myelomas, Multiple

First Posted Date: 2020-11-27

Last Posted Date: 2024-12-11

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 2300

Registration Number: NCT04645199

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Eltrombopag for Chemotherapy-induced Thrombocytopenia

Phase 2

Recruiting

Conditions: Chemotherapy-induced Thrombocytopenia
Eltrombopag

Interventions: Drug: Eltrombopag

First Posted Date: 2020-10-23

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 50

Registration Number: NCT04600960

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Phase 4

Conditions: Primary Immune Thrombocytopenia (ITP)

Interventions: Drug: eltrombopag combining rituximab
Drug: eltrombopag

First Posted Date: 2020-08-19

Last Posted Date: 2020-08-19

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 224

Registration Number: NCT04518475

Locations: 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Phase 2

Recruiting

Conditions: Waldenström Macroglobulinemia

Interventions: Drug: Zanubrutinib,Ixazomib and Dexamethasone

First Posted Date: 2020-07-09

Last Posted Date: 2020-07-10

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 55

Registration Number: NCT04463953

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy